Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $28.1 million.

  • Allogene Therapeutics' Accumulated Expenses rose 394.98% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 394.98%. This contributed to the annual value of $30.1 million for FY2024, which is 337.69% down from last year.
  • Allogene Therapeutics' Accumulated Expenses amounted to $28.1 million in Q3 2025, which was up 394.98% from $26.8 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Accumulated Expenses ranged from a high of $44.6 million in Q1 2023 and a low of $24.4 million during Q2 2024
  • Its 5-year average for Accumulated Expenses is $33.2 million, with a median of $31.2 million in 2023.
  • Per our database at Business Quant, Allogene Therapeutics' Accumulated Expenses soared by 10253.33% in 2021 and then plummeted by 4494.5% in 2024.
  • Allogene Therapeutics' Accumulated Expenses (Quarter) stood at $37.5 million in 2021, then rose by 5.99% to $39.7 million in 2022, then decreased by 21.54% to $31.2 million in 2023, then fell by 3.38% to $30.1 million in 2024, then fell by 6.62% to $28.1 million in 2025.
  • Its Accumulated Expenses stands at $28.1 million for Q3 2025, versus $26.8 million for Q2 2025 and $25.0 million for Q1 2025.